Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push
The FDA is awarding national priority vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics for their psychedelic treatments.
By FierceBiotech
· Apr 26, 2026
· via FierceBiotech
Image: FierceBiotech
Tags
policyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
![<![CDATA[Contributor: Prior Authorization in 2026—CMS Is Rebuilding the Operating Model]]>](https://healthcare-images.dcutler.workers.dev/images/article-images/cdata-contributor-prior-authorization-in-2026-cms-is-rebuild.png)
PolicySTAT News ↗
A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called fo…
PolicyDrug Channels ↗
By Bryce Platt, PharmD Minnesota’s new 340B data reveal a growing disconnect between the program’s size and th…